全球定位标记市场－产业规模、份额、趋势、机会和预测，按产品、治疗方式、癌症类型、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球定位标记市场规模为9,738万美元，预计2030年将以5.3%的复合年增长率成长至1.3275亿美元。定位标记是一种小型可植入物体，用于医学影像中，为放射治疗和外科手术提供精确的参考点，从而实现肿瘤的精准定位并最大限度地减少对健康组织的损伤。全球定位标记市场的主要驱动力是全球癌症发生率的上升、MRI和CBCT等先进影像技术的广泛应用以及精准放射治疗技术的持续进步。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球标记物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品分类（金属基标记物、聚合物基标记物、其他定位标记）
  • 按检查方式（CT/CBCT、MRI、超音波、放射治疗）
  • 依癌症类型（摄护腺癌、肺癌、乳癌、胃癌、其他癌症）
  • 按最终使用者（医院和诊所、独立放射治疗中心、癌症研究中心）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美标记物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲标记物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区标记物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲标记物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲标记物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球标记物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• CIVCO Radiotherapy
• IZI Medical Products
• Boston Scientific Corporation
• Naslund Medical AB
• Best Medical International, Inc.
• Nanovi A/S
• Carbon Medical Technologies Inc.
• Eckert & Ziegler
• Innovative Oncology Solutions
• Medtronic plc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Fiducial Markers Market, valued at USD 97.38 Million in 2024, is projected to experience a CAGR of 5.3% to reach USD 132.75 Million by 2030. Fiducial markers are small, implantable objects utilized in medical imaging to establish precise reference points for guiding radiation therapy and surgical procedures, thereby enabling accurate tumor localization and minimizing collateral damage to healthy tissue. The global market for these markers is primarily propelled by the increasing worldwide incidence of cancer, the expanding adoption of advanced imaging modalities like MRI and CBCT, and continuous technological advancements in precision radiotherapy techniques.

Key Market Drivers

The rising global incidence of cancer significantly propels demand for fiducial markers by expanding the patient population requiring precise radiation therapy. Growing cancer prevalence necessitates accurate tumor localization, particularly in sensitive anatomical regions. Fiducial markers are essential for precision in modern oncology, enhancing therapeutic efficacy and minimizing collateral damage. According to the American Cancer Society, in April 2024, lung cancer was the most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases globally, highlighting a substantial disease burden often necessitating targeted radiation treatment. This prevalence drives continuous demand for accurate therapeutic guidance.

Key Market Challenges

The significant cost associated with fiducial marker implantation procedures presents a considerable impediment to the growth of the Global Fiducial Markers Market. These expenses, encompassing the markers, surgical expertise, specialized equipment, and necessary follow-up imaging for precise placement, restrict widespread adoption. This high expenditure is particularly challenging within healthcare systems facing budget constraints or limited reimbursement policies, directly impacting market penetration and resulting in lower utilization rates despite the acknowledged benefits of improved treatment accuracy and reduced collateral damage.

Key Market Trends

Biodegradable marker development addresses patient comfort and reduces the need for secondary removal procedures, thereby enhancing patient outcomes and potentially reducing healthcare costs. This innovation aligns with the broader medical shift toward sustainable and patient-friendly solutions. The American Medical Association, at its 2023 Interim Meeting, referred Resolution 2-I-23 concerning single-use/disposable medical devices, acknowledging the need to address adverse environmental consequences and balance fiscal expense with patient safety concerns, which reflects the growing recognition of biodegradable material benefits.

Key Market Players

• CIVCO Radiotherapy
• IZI Medical Products
• Boston Scientific Corporation
• Naslund Medical AB
• Best Medical International, Inc.
• Nanovi A/S
• Carbon Medical Technologies Inc.
• Eckert & Ziegler
• Innovative Oncology Solutions
• Medtronic plc

Report Scope:

In this report, the Global Fiducial Markers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fiducial Markers Market, By Product:

• Metal-based Markers
• Polymer-based Markers
• Other Fiducial Markers

Fiducial Markers Market, By Modality:

• CT/CBCT
• MRI
• Ultrasound
• Radiotherapy

Fiducial Markers Market, By Cancer Type:

• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Gastric Cancer
• Other Cancers

Fiducial Markers Market, By End user:

• Hospitals & Clinics
• Independent Radiotherapy Centers
• Cancer Research Centers

Fiducial Markers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Fiducial Markers Market.

Available Customizations:

Global Fiducial Markers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fiducial Markers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Metal-based Markers, Polymer-based Markers, Other Fiducial Markers)
  • 5.2.2. By Modality (CT/CBCT, MRI, Ultrasound, Radiotherapy)
  • 5.2.3. By Cancer Type (Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, Other Cancers)
  • 5.2.4. By End user (Hospitals & Clinics, Independent Radiotherapy Centers, Cancer Research Centers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Fiducial Markers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Modality
  • 6.2.3. By Cancer Type
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Fiducial Markers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Modality
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Fiducial Markers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Modality
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Fiducial Markers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Modality
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By End user

7. Europe Fiducial Markers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Modality
  • 7.2.3. By Cancer Type
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Fiducial Markers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Modality
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By End user
  • 7.3.2. France Fiducial Markers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Modality
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Fiducial Markers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Modality
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Fiducial Markers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Modality
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Fiducial Markers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Modality
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By End user

8. Asia Pacific Fiducial Markers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Modality
  • 8.2.3. By Cancer Type
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Fiducial Markers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Modality
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By End user
  • 8.3.2. India Fiducial Markers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Modality
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Fiducial Markers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Modality
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Fiducial Markers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Modality
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Fiducial Markers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Modality
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By End user

9. Middle East & Africa Fiducial Markers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Modality
  • 9.2.3. By Cancer Type
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Fiducial Markers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Modality
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Fiducial Markers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Modality
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Fiducial Markers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Modality
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By End user

10. South America Fiducial Markers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Modality
  • 10.2.3. By Cancer Type
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Fiducial Markers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Modality
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Fiducial Markers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Modality
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Fiducial Markers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Modality
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Fiducial Markers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. CIVCO Radiotherapy
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. IZI Medical Products
• 15.3. Boston Scientific Corporation
• 15.4. Naslund Medical AB
• 15.5. Best Medical International, Inc.
• 15.6. Nanovi A/S
• 15.7. Carbon Medical Technologies Inc.
• 15.8. Eckert & Ziegler
• 15.9. Innovative Oncology Solutions
• 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer